- Non-Curative Resection: Should Clinicians Consider Providing Additional Surgery for All Patients?
-
Hatta W, Gotoda T, Masamune A
- KMID: 2500877
- Clin Endosc.
- 2020 Mar;53(2):109-110.
- doi: 10.5946/ce.2020.043
-
- CITED
-
- Close
- SHARE
-
- Close
- A Recent Argument for the Use of Endoscopic Submucosal Dissection for Early Gastric Cancers
-
Hatta W, Gotoda T, Koike T, Masamune A
- KMID: 2504150
- Gut Liver.
- 2020 Jul;14(4):412-422.
- doi: 10.5009/gnl19194
Endoscopic submucosal dissection (ESD) has become the standard treatment method for early gastric cancers (EGCs) due to the negligible risk for lymph node metastasis (LNM) in Eastern Asian countries. According... -
- CITED
-
- Close
- SHARE
-
- Close
- White spots around colorectal tumors are cancer-related findings and may aid endoscopic diagnosis: a prospective study in Japan
-
Korekawa K, Shimoyama Y, Fujishima F, Nagai H, Naito T, Moroi R, Shiga H, Kakuta Y, Kinouchi Y, Masamune A
- KMID: 2559215
- Clin Endosc.
- 2024 Sep;57(5):637-646.
- doi: 10.5946/ce.2024.027
Background/Aims: During endoscopy, white spots (WS) are sometimes observed around benign or malignant colorectal tumors; however, few reports have investigated WS, and their significance remains unknown. Therefore, we investigated the... -
- CITED
-
- Close
- SHARE
-
- Close
- Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab
-
Shiga H, Nagai H, Shimoyama Y, Naito T, Moroi R, Kakuta Y, Kinouchi Y, Masamune A
- KMID: 2558197
- Intest Res.
- 2024 Jul;22(3):378-386.
- doi: 10.5217/ir.2023.00203
Background/Aims: Vedolizumab (VDZ) is a gut-selective agent with a favorable safety profile. We aimed to assess the feasibility of elective switch from other advanced therapies to VDZ and subsequent live-attenuated... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
-
Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T
- KMID: 2438448
- Intest Res.
- 2019 Jan;17(1):94-106.
- doi: 10.5217/ir.2018.00048
BACKGROUND/AIMS: Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them... -
- CITED
-
- Close
- SHARE
-
- Close
